| Name | Title | Contact Details |
|---|
The Victorian Department of Health & Human Services develops and delivers policies, programs and services that support and enhance the wellbeing of all Victorians.
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
Somnia Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New Rochelle, NY. To find more information about Somnia Inc, please visit www.somniainc.com
Varian Medical Systems` vision is a world without fear of cancer. To meet this challenge, we equip the world with new tools for fighting cancer. Since the 1950s we have been producing tools that harness the power of X-ray energy to benefit humankind. Our history is one of pioneering developments in the fields of radiotherapy, radiosurgery, X-ray tube technology, digital image detectors, cargo screening, and non-destructive testing. Today, we have a robust product portfolio and long-standing relationships with many of the world`s leading clinicians. As Varian continues to grow, our staff of over 6,500 people in 70 sales and support offices around the globe is developing innovative, cost-effective solutions that help make the world a healthier place. Varian reserves the right to remove any comment for any reason and ban any user from its page at is sole discretion. Varian does not endorse user comments on its page and cannot confirm their accuracy. User comments do not necessarily represent the ideas, thoughts, beliefs, opinions or views of Varian, or any of its affiliates.
Kedrion Biopharma develops and produces plasma-derived therapies, making them available to meet patients` needs the world over. We collect and fractionate blood plasma for the development, production and distribution of plasma derivatives used in the treatment of patients suffering from rare and chronic conditions such as hemophilia and immune system deficiencies. A corporation is not a person, but a corporation is run by people and it affects people. And Kedrion`s business is people. The very nature of our enterprise is to help people live more full and healthy lives. This commitment extends to how we conduct our business, that is, in ways that are consistent with our mission: to build bridges that.benefit people. Long a major player in the plasma derivatives sector in Italy, as partner with the Italian Health System, Kedrion has now become an international participant in the industry with a market presence in about 100 countries. We have plants in Italy, Hungary and the United States and plasma collection centers in the U.S., Germany and Hungary. Kedrion looks forward to continued expansion and the wider sharing of its experience, know-how and technology to foster self-sufficiency of plasma-derived therapies worldwide and to bring healthier and less restricted lives to people suffering from rare disorders. Kedrion Biopharma produces wealth for investors, employees and for the local community, consistent with its own vision and values: responsibility, transparency, confidence in and respect for people. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion Biopharma builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.